Baldness Drugs Emerge as Wall Street's Next Goldmine as Novel Treatments Near Market
核心洞察
Pattern hair loss (搜索) affects an estimated 50 million men and 30 million women in the US, yet no new drugs have been approved since the late 1990s.
Cosmo's topical clascoterone, which blocks the hormone causing hair loss at the follicle, is slated for a US new drug application in Q1 2027.
Veradermics reported positive results for a minoxidil tablet in male-pattern hair loss (搜索) and promising mid-stage data in women, potentially becoming the first approved pill for female-pattern hair loss.
Pattern hair loss (搜索) affects an estimated 50 million men and 30 million women in the United States, yet no new drugs have been approved in this category since the late 1990s. That unmet need has turned the hair-loss treatment space into Wall Street's next major investment theme, sending shares of Veradermics Inc., which trades under the ticker "MANE," up nearly 500% since its February initial public offering, while Absci Corp. (搜索)'s stock has more than doubled so far in 2026.
The current treatment landscape remains limited. Patients who are ineligible for hair transplant surgery — or who cannot afford it — are left with two main options: over-the-counter topical minoxidil, the active ingredient in Rogaine, or prescription finasteride, branded as Propecia. Both carry notable side effects; minoxidil has been linked to heart palpitations, while finasteride is known to lower sex drive. Wall Street views new treatments as an untapped goldmine of consumers willing to pay out-of-pocket for better options, drawing parallels to the boom in GLP-1 weight-loss drugs.
"People will fly all the way to Turkey to have some hair moved around on their head," said Needham analyst Gil Blum, who rates Absci a buy. "Can you imagine if you could do that without getting a hair transplant?"
Cosmo's Clascoterone Leads the Race to Market
One of the closest candidates to market is Cosmo NV (搜索)'s topical medicine, clascoterone, which targets the root cause of male-pattern hair loss (搜索) by blocking the hormone that causes it directly at the hair follicle. The clascoterone 5% topical solution leverages the same active ingredient used in Winlevi, Cosmo's acne treatment product.
Cosmo says the treatment could be the "single biggest opportunity" in its portfolio and plans to submit a new drug application to US regulators in the first quarter of 2027. Jefferies analysts estimate sales for Cosmo's male hair-loss therapy could reach $3 billion globally, "assuming a capable commercial partner is successfully found." The brokerage suggested the company may find a partner before the end of the year, which could help bolster the share price. While new medicines are likely more than a year away from hitting US shelves, analysts expect Cosmo shares to nearly double over the next 12 months.
Veradermics Pursues a First-in-Class Oral Option
Veradermics announced positive results for its lead candidate, a tablet formulation of minoxidil, in male-pattern hair loss (搜索) in April. The company also reported promising mid-stage data for women with thinning hair in July. If it wins approval from the Food and Drug Administration, the drug could become the first approved pill for female-pattern hair loss.
Analysts tracked by Bloomberg are universally bullish on both Cosmo and Veradermics. "This space definitely can accommodate multiple drugs," said Jefferies analyst Roger Song, who holds the Street's highest price target on Veradermics. "Many hair loss patients tend to use multiple drugs, either prescription or over-the-counter — as long as they can afford it — because it's a cash-pay market."
Absci's AI-Designed Injectable Awaits Clinical Data
Absci is developing its early-stage drug candidate ABS-201, an AI-designed shot to treat pattern hair loss (搜索). The firm expects interim data in the second half of 2026. Needham's Gil Blum described the company's story as a "zero or hero" scenario, noting the potential returns could be substantial but that key clinical validation for the early-stage program is still to come. "This is a zero or hero story. I would buy it now because it's still cheap," Blum said of Absci.
A Cash-Pay Market with Real Risks
Unlike weight-loss drugs, going bald is not a health crisis. GLP-1s secured insurance coverage as a weapon in the battle against obesity while also attracting consumers interested in meeting modern beauty standards. Hair-loss drugs, by contrast, are likely to remain out-of-pocket expenses for consumers, though many in the industry remain upbeat on future sales.
"Both obesity and hair loss are large consumer markets and that's one reason why both of those categories can offer significant revenue potential," said OrbiMed's Geoff Hsu, portfolio manager of the Biotech Growth Trust Plc. "If you do find a safe and efficacious drug for hair loss, that would unlock a significant addressable market."
Ryan Isherwood, who with his wife owns three Gameday Men's Health clinics in Wisconsin, pointed to the appeal of simpler administration. "If you can make it easier on the patient — that is pain-free and simple like taking a pill — I think it opens a whole new avenue of potential patients to treat," he said.
Drug development remains high risk, with the potential for big returns counterbalanced by products and companies that flop. Before GLP-1s won over insurers and consumers alike, a whole generation of obesity drugs failed to reach blockbuster status, and some instead went to bankruptcy court.